The potential of modulating small RNA activity in in vivo

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 235-248

  van Mil, Alain ^a,b   Doevendans, Pieter A ^a,b   Sluijter, Joost P G ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Gene knockdown; In vivo therapy; miRNA; RNAi

Indexed keywords

2' FLUORO RNA; ADENOVIRUS VECTOR; APTAMER; ATELOCOLLAGEN; CARDIOLIPIN; CHITOSAN; CHOLESTEROL; COMPLEMENTARY RNA; CYCLODEXTRIN; DICER; LENTIVIRUS VECTOR; LIPID; LIPOSOME; MESSENGER RNA; MICRORNA; MICROSPHERE; NANOPARTICLE; OLIGOMER; PARVOVIRUS VECTOR; PHOSPHOROTHIOATE RNA; POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; RNA; SHORT HAIRPIN RNA; SINGLE STRANDED RNA; SMALL INTERFERING RNA; SMALL RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNMODIFIED SMALL RNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AMINO TERMINAL SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BASE PAIRING; DNA CONFORMATION; DNA METHYLATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; GENETIC ENGINEERING; HUMAN; IN VIVO GENE TRANSFER; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; POSTTRANSCRIPTIONAL GENE SILENCING; PROTEIN RNA BINDING; REVIEW; RNA CLEAVAGE; RNA INTERFERENCE; RNA SEQUENCE; RNA SYNTHESIS; SINGLE DRUG DOSE; TUMOR; VIRAL GENE DELIVERY SYSTEM; ANIMAL; DRUG EFFECT; METABOLISM;

ANIMALS; HUMANS; MICRORNAS; RNA INTERFERENCE;

EID: 65449128109     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709787316029     Document Type: Review

References (159)

1. Stephenson, M.L.; Zamecnik, P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA, 1978, 75, 285-8.
2. Zamecnik, P.C.; Stephenson, M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligode-oxynucleotide. Proc. Natl. Acad. Sci. USA, 1978, 75, 280-4.
3. Scherer, L.J.; Rossi, J.J. Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol., 2003, 21, 1457-65.
4. Cech, T.R.; Zaug, A.J.; Grabowski, P.J. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell, 1981, 27, 487-96.
5. Forster, A.C.; Altman, S. External guide sequences for an RNA enzyme. Science, 1990, 249, 783-6.
6. Trang, P.; Kilani, A.; Kim, J.; Liu, F. A ribozyme derived from the catalytic subunit of RNase P from Escherichia coli is highly effective in inhibiting replication of herpes simplex virus 1. J. Mol. Biol., 2000, 301, 817-26.
7. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998, 391, 806-11.
8. Zamore, P.D.; Tuschl, T.; Sharp, P.A.; Bartel, D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 2000, 101, 25-33.
9. Napoli, C.; Lemieux, C.; Jorgensen, R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible cosuppression of homologous genes in trans. Plant Cell, 1990, 2, 279-89.
10. Hammond, S.M.; Bernstein, E.; Beach, D.; Hannon, G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature, 2000, 404, 293-6.
11. Kennerdell, J.R.; Carthew, R.W. Heritable gene silencing in Drosophila using double-stranded RNA. Nat. Biotechnol., 2000, 18, 896-8.
12. Li, Y.X.; Farrell, M.J.; Liu, R.; Mohanty, N.; Kirby, M.L. Double-stranded RNA injection produces null phenotypes in zebrafish. Dev. Biol., 2000, 217, 394-405.
13. Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411, 494-8.
14. Elbashir, S.M.; Lendeckel, W.; Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev., 2001, 15, 188-200.
15. Bernstein, E.; Caudy, A.A.; Hammond, S.M.; Hannon, G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 2001, 409, 363-6.
16. Brummelkamp, T.R.; Bernards, R.; Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science, 2002, 296, 550-3.
17. Collins, R.E.; Cheng, X. Structural domains in RNAi. FEBS Lett., 2005, 579, 5841-9.
18. Schwarz, D.S.; Hutvagner, G.; Du, T.; Xu, Z.; Aronin, N.; Zamore, P.D. Asymmetry in the assembly of the RNAi enzyme complex. Cell, 2003, 115, 199-208.
19. Khvorova, A.; Reynolds, A.; Jayasena, S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell, 2003, 115, 209-16.
20. Rand, T.A.; Petersen, S.; Du, F.; Wang, X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell, 2005, 123, 621-9.
21. Nykanen, A.; Haley, B.; Zamore, P.D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell, 2001, 107, 309-21.
22. Martinez, J.; Patkaniowska, A.; Urlaub, H.; Luhrmann, R.; Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell, 2002, 110, 563-74.
23. Liu, J.; Carmell, M.A.; Rivas, F.V.; Marsden, C.G.; Thomson, J.M.; Song, J.J.; Hammond, S.M.; Joshua-Tor, L.; Hannon, G.J. Argonaute2 is the catalytic engine of mammalian RNAi. Science, 2004, 305, 1437-41.
24. Rand, T.A.; Ginalski, K.; Grishin, N.V.; Wang, X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc. Natl. Acad. Sci. USA, 2004, 101, 14385-9.
25. Gitlin, L.; Andino, R. Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing. J. Virol., 2003, 77, 7159-65.
26. Lecellier, C.H.; Dunoyer, P.; Arar, K.; Lehmann-Che, J.; Eyquem, S.; Himber, C.; Saib, A.; Voinnet, O. A cellular microRNA mediates antiviral defense in human cells. Science, 2005, 308, 557-60.
27. Sijen, T.; Plasterk, R.H. Transposon silencing in the Caenorhabditis elegans germ line by natural RNAi. Nature, 2003, 426, 310-4.
28. Lippman, Z.; Martienssen, R. The role of RNA interference in heterochromatic silencing. Nature, 2004, 431, 364-70.
29. Tang, G. siRNA and miRNA: an insight into RISCs. Trends Biochem. Sci., 2005, 30, 106-14.
30. Lim, L.P.; Lau, N.C.; Garrett-Engele, P.; Grimson, A.; Schelter, J.M.; Castle, J.; Bartel, D.P.; Linsley, P.S.; Johnson, J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 2005, 433, 769-73.
31. Volpe, T.A.; Kidner, C.; Hall, I.M.; Teng, G.; Grewal, S.I.; Martienssen, R.A. Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science, 2002, 297, 1833-7.
32. Kawasaki, H.; Taira, K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature, 2004, 431, 211-7.
33. Lee, R.C.; Ambros, V. An extensive class of small RNAs in Caenorhabditis elegans. Science, 2001, 294, 862-4.
34. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75, 843-54.
35. Lai, E.C. microRNAs: runts of the genome assert themselves. Curr. Biol., 2003, 13, R925-36.
36. Ambros, V. The functions of animal microRNAs. Nature, 2004, 431, 350-5.
37. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116, 281-97.
38. Zeng, Y.; Yi, R.; Cullen, B.R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl. Acad. Sci. USA, 2003, 100, 9779-84.
39. Lee, Y.; Ahn, C.; Han, J.; Choi, H.; Kim, J.; Yim, J.; Lee, J.; Provost, P.; Radmark, O.; Kim, S.; Kim, V.N. The nuclear RNase III Drosha initiates microRNA processing. Nature, 2003, 425, 415-9.
40. Denli, A.M.; Tops, B.B.; Plasterk, R.H.; Ketting, R.F.; Hannon, G.J. Processing of primary microRNAs by the Microprocessor complex. Nature, 2004, 432, 231-5.
41. Gregory, R.I.; Yan, K.P.; Amuthan, G.; Chendrimada, T.; Doratotaj, B.; Cooch, N.; Shiekhattar, R. The Microprocessor complex mediates the genesis of microRNAs. Nature, 2004, 432, 235-40.
42. Yi, R.; Qin, Y.; Macara, I.G.; Cullen, B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev., 2003, 17, 3011-6.
43. Lund, E.; Guttinger, S.; Calado, A.; Dahlberg, J.E.; Kutay, U. Nuclear export of microRNA precursors. Science, 2004, 303, 95-8.
44. Yekta, S.; Shih, I.H.; Bartel, D.P. MicroRNA-directed cleavage of HOXB8 mRNA. Science, 2004, 304, 594-6.
45. Griffiths-Jones, S. The microRNA Registry. Nucleic Acids Res., 2004, 32, D109-11.
46. Bentwich, I.; Avniel, A.; Karov, Y.; Aharonov, R.; Gilad, S.; Barad, O.; Barzilai, A.; Einat, P.; Einav, U.; Meiri, E.; Sharon, E.; Spector, Y.; Bentwich, Z. Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet., 2005, 37, 766-70.
47. miRBase:. The home of microRNA data. http://microrna.sanger.ac.uk/ sequences/ (2008).
48. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120, 15-20.
49. Rajewsky, N. microRNA target predictions in animals. Nat. Genet., 2006, 38 (Suppl), S8-13.
50. Lagos-Quintana, M.; Rauhut, R.; Yalcin, A.; Meyer, J.; Lendeckel, W.; Tuschl, T. Identification of tissue-specific microRNAs from mouse. Curr. Biol., 2002, 12, 735-9.
51. Wienholds, E.; Kloosterman, W.P.; Miska, E.; Alvarez-Saavedra, E.; Berezikov, E.; de Bruijn, E.; Horvitz, H.R.; Kauppinen, S.; Plasterk, R.H. MicroRNA expression in zebrafish embryonic development. Science, 2005, 309, 310-1.
52. Calin, G.A.; Croce, C.M. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res., 2006, 66, 7390-4.
53. Hutvagner, G.; Simard, M.J.; Mello, C.C.; Zamore, P.D. Sequence-specific inhibition of small RNA function. PLoS Biol., 2004, 2, E98.
54. Meister, G.; Landthaler, M.; Dorsett, Y.; Tuschl, T. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA, 2004, 10, 544-50.
55. Zhang, C.; Pei, J.; Kumar, D.; Sakabe, I.; Boudreau, H.E.; Gokhale, P.C.; Kasid, U.N. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. Methods Mol. Biol., 2007, 361, 163-85.
56. Aigner, A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl. Microbiol. Biotechnol., 2007, 76, 9-21.
57. Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W.S.; Khvorova, A. Rational siRNA design for RNA interference. Nat. Biotechnol., 2004, 22, 326-30.
58. Karkare, S.; Daniel, S.; Bhatnagar, D. RNA interference silencing the transcriptional message: aspects and applications. Appl. Biochem. Biotechnol., 2004, 119, 1-12.
59. Amarzguioui, M.; Rossi, J.J.; Kim, D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett., 2005, 579, 5974-81.
60. Tuschl, T.; Elbashir, S.; Harborth, J.; Weber, K. The siRNA user guide. http://www.rockefeller.edu/labheads/tuschl/sirna.html (2008).
61. Li, L.; Lin, X.; Khvorova, A.; Fesik, S.W.; Shen, Y. Defining the optimal parameters for hairpin-based knockdown constructs. RNA, 2007, 13, 1765-74.
62. Bohula, E.A.; Salisbury, A.J.; Sohail, M.; Playford, M.P.; Riedemann, J.; Southern, E.M.; Macaulay, V.M. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J. Biol. Chem., 2003, 278, 15991-7.
63. Ding, Y.; Lawrence, C.E. A statistical sampling algorithm for RNA secondary structure prediction. Nucleic Acids Res., 2003, 31, 7280-301.
64. Kretschmer-Kazemi Far, R.; Sczakiel, G. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res., 2003, 31, 4417-24.
65. Vickers, T.A.; Koo, S.; Bennett, C.F.; Crooke, S.T.; Dean, N.M.; Baker, B.F. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem., 2003, 278, 7108-18.
66. Jackson, A.L.; Bartz, S.R.; Schelter, J.; Kobayashi, S.V.; Burchard, J.; Mao, M.; Li, B.; Cavet, G.; Linsley, P.S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol., 2003, 21, 635-7.
67. Birmingham, A.; Anderson, E.M.; Reynolds, A.; Ilsley-Tyree, D.; Leake, D.; Fedorov, Y.; Baskerville, S.; Maksimova, E.; Robinson, K.; Karpilow, J.; Marshall, W.S.; Khvorova, A. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods, 2006, 3, 199-204.
68. Grimm, D.; Streetz, K.L.; Jopling, C.L.; Storm, T.A.; Pandey, K.; Davis, C.R.; Marion, P.; Salazar, F.; Kay, M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 2006, 441, 537-41.
69. Castanotto, D.; Sakurai, K.; Lingeman, R.; Li, H.; Shively, L.; Aagaard, L.; Soifer, H.; Gatignol, A.; Riggs, A.; Rossi, J.J. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res., 2007, 35, 5154-64.
70. John, M.; Constien, R.; Akinc, A.; Goldberg, M.; Moon, Y.A.; Spranger, M.; Hadwiger, P.; Soutschek, J.; Vornlocher, H.P.; Manoharan, M.; Stoffel, M.; Langer, R.; Anderson, D.G.; Horton, J.D.; Koteliansky, V.; Bumcrot, D. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature, 2007, 449, 745-7.
71. Bridge, A.J.; Pebernard, S.; Ducraux, A.; Nicoulaz, A.L.; Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet., 2003, 34, 263-4.
72. Sledz, C.A.; Holko, M.; de Veer, M.J.; Silverman, R.H.; Williams, B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol., 2003, 5, 834-9.
73. Kariko, K.; Bhuyan, P.; Capodici, J.; Weissman, D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol., 2004, 172, 6545-9.
74. Hornung, V.; Guenthner-Biller, M.; Bourquin, C.; Ablasser, A.; Schlee, M.; Uematsu, S.; Noronha, A.; Manoharan, M.; Akira, S.; de Fougerolles, A.; Endres, S.; Hartmann, G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med., 2005, 11, 263-70.
75. Sioud, M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol., 2005, 348, 1079-90.
76. Kim, D.H.; Longo, M.; Han, Y.; Lundberg, P.; Cantin, E.; Rossi, J.J. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol., 2004, 22, 321-5.
77. Judge, A.D.; Sood, V.; Shaw, J.R.; Fang, D.; McClintock, K.; MacLachlan, I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol., 2005, 23, 457-62.
78. Reynolds, A.; Anderson, E.M.; Vermeulen, A.; Fedorov, Y.; Robinson, K.; Leake, D.; Karpilow, J.; Marshall, W.S.; Khvorova, A. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA, 2006, 12, 988-93.
79. Lewis, D.L.; Hagstrom, J.E.; Loomis, A.G.; Wolff, J.A.; Herweijer, H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet., 2002, 32, 107-8.
80. McCaffrey, A.P.; Meuse, L.; Pham, T.T.; Conklin, D.S.; Hannon, G.J.; Kay, M.A. RNA interference in adult mice. Nature, 2002, 418, 38-9.
81. Hannon, G.J. RNA interference. Nature, 2002, 418, 244-51.
82. Xia, H.; Mao, Q.; Paulson, H.L.; Davidson, B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol., 2002, 20, 1006-10.
83. Xia, H.; Mao, Q.; Eliason, S.L.; Harper, S.Q.; Martins, I.H.; Orr, H.T.; Paulson, H.L.; Yang, L.; Kotin, R.M.; Davidson, B.L. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med., 2004, 10, 816-20.
84. Uprichard, S.L.; Boyd, B.; Althage, A.; Chisari, F.V. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc. Natl. Acad. Sci. USA, 2005, 102, 773-8.
85. Paskowitz, D.M.; Greenberg, K.P.; Yasumura, D.; Grimm, D.; Yang, H.; Duncan, J.L.; Kay, M.A.; Lavail, M.M.; Flannery, J.G.; Vollrath, D. Rapid and stable knockdown of an endogenous gene in retinal pigment epithelium. Hum. Gene Ther., 2007, 18, 871-80.
86. Rubinson, D.A.; Dillon, C.P.; Kwiatkowski, A.V.; Sievers, C.; Yang, L.; Kopinja, J.; Rooney, D.L.; Zhang, M.; Ihrig, M.M.; McManus, M.T.; Gertler, F.B.; Scott, M.L.; Van Parijs, L. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet., 2003, 33, 401-6.
87. Raoul, C.; Abbas-Terki, T.; Bensadoun, J.C.; Guillot, S.; Haase, G.; Szulc, J.; Henderson, C.E.; Aebischer, P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med., 2005, 11, 423-8.
88. Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; Le Deist, F.; Wulffraat, N.; McIntyre, E.; Radford, I.; Villeval, J.L.; Fraser, C.C.; Cavazzana-Calvo, M.; Fischer, A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 2003, 348, 255-6.
89. Mittal, V. Improving the efficiency of RNA interference in mammals. Nat. Rev. Genet., 2004, 5, 355-65.
90. Flotte, T.R. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther., 2004, 11, 805-10.
91. Mandel, R.J.; Burger, C. Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr. Opin. Mol. Ther., 2004, 6, 482-90.
92. Nakai, H.; Yant, S.R.; Storm, T.A.; Fuess, S.; Meuse, L.; Kay, M.A. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol., 2001, 75, 6969-76.
93. Dykxhoorn, D.M.; Novina, C.D.; Sharp, P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol., 2003, 4, 457-67.
94. Hannon, G.J.; Rossi, J.J. Unlocking the potential of the human genome with RNA interference. Nature, 2004, 431, 371-8.
95. Zhang, G.; Gao, X.; Song, Y.K.; Vollmer, R.; Stolz, D.B.; Gasiorowski, J.Z.; Dean, D.A.; Liu, D. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther., 2004, 11, 675-82.
96. Reich, S.J.; Fosnot, J.; Kuroki, A.; Tang, W.; Yang, X.; Maguire, A.M.; Bennett, J.; Tolentino, M.J. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis., 2003, 9, 210-6.
97. Dorn, G.; Patel, S.; Wotherspoon, G.; Hemmings-Mieszczak, M.; Barclay, J.; Natt, F.J.; Martin, P.; Bevan, S.; Fox, A.; Ganju, P.; Wishart, W.; Hall, J. siRNA relieves chronic neuropathic pain. Nucleic Acids Res., 2004, 32, e49.
98. Zhang, X.; Shan, P.; Jiang, D.; Noble, P.W.; Abraham, N.G.; Kappas, A.; Lee, P.J. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem., 2004, 279, 10677-84.
99. Aharinejad, S.; Paulus, P.; Sioud, M.; Hofmann, M.; Zins, K.; Schafer, R.; Stanley, E.R.; Abraham, D. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res., 2004, 64, 5378-84.
100. Layzer, J.M.; McCaffrey, A.P.; Tanner, A.K.; Huang, Z.; Kay, M.A.; Sullenger, B.A. In vivo activity of nuclease-resistant siRNAs. RNA, 2004, 10, 766-71.
101. Amarzguioui, M.; Holen, T.; Babaie, E.; Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res., 2003, 31, 589-95.
102. Braasch, D.A.; Jensen, S.; Liu, Y.; Kaur, K.; Arar, K.; White, M.A.; Corey, D.R. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry, 2003, 42, 7967-75.
103. Harborth, J.; Elbashir, S.M.; Vandenburgh, K.; Manninga, H.; Scaringe, S.A.; Weber, K.; Tuschl, T. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev., 2003, 13, 83-105.
104. Braasch, D.A.; Paroo, Z.; Constantinescu, A.; Ren, G.; Oz, O.K.; Mason, R.P.; Corey, D.R. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett., 2004, 14, 1139-43.
105. Levin, A.A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta, 1999, 1489, 69-84.
106. Parrish, S.; Fleenor, J.; Xu, S.; Mello, C.; Fire, A. Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol. Cell, 2000, 6, 1077-87.
107. Morrissey, D.V.; Blanchard, K.; Shaw, L.; Jensen, K.; Lockridge, J.A.; Dickinson, B.; McSwiggen, J.A.; Vargeese, C.; Bowman, K.; Shaffer, C.S.; Polisky, B.A.; Zinnen, S. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology, 2005, 41, 1349-56.
108. Morrissey, D.V.; Lockridge, J.A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V.; Vaish, N.; Zinnen, S.; Vargeese, C.; Bowman, K.; Shaffer, C.S.; Jeffs, L.B.; Judge, A.; MacLachlan, I.; Polisky, B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. , 2005, 23, 1002-7.
109. Judge, A.D.; Bola, G.; Lee, A.C.; MacLachlan, I. Design of non-inflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther., 2006, 13, 494-505.
110. Kim, J.Y.; Choung, S.; Lee, E.J.; Kim, Y.J.; Choi, Y.C. Immune activation by siRNA/liposome complexes in mice is sequence- independent: lack of a role for Toll-like receptor 3 signaling. Mol. Cells, 2007, 24, 247-54.
111. Shin, D.; Kim, S.I.; Park, M.; Kim, M. Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. Biochem. Biophys. Res. Commun., 2007, 364, 436-42.
112. Elmen, J.; Thonberg, H.; Ljungberg, K.; Frieden, M.; Westergaard, M.; Xu, Y.; Wahren, B.; Liang, Z.; Orum, H.; Koch, T.; Wahlestedt, C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res., 2005, 33, 439-47.
113. Mook, O.R.; Baas, F.; de Wissel, M.B.; Fluiter, K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol. Cancer Ther., 2007, 6, 833-43.
114. Sioud, M.; Sorensen, D.R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun., 2003, 312, 1220-5.
115. Sorensen, D.R.; Leirdal, M.; Sioud, M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol., 2003, 327, 761-6.
116. Hassan, A.; Tian, Y.; Zheng, W.; Ji, H.; Sandberg, K.; Verbalis, J.G. Small interfering RNA-mediated functional silencing of vaso-pressin V2 receptors in the mouse kidney. Physiol. Genomics, 2005, 21, 382-8.
117. Yano, J.; Hirabayashi, K.; Nakagawa, S.; Yamaguchi, T.; Nogawa, M.; Kashimori, I.; Naito, H.; Kitagawa, H.; Ishiyama, K.; Ohgi, T.; Irimura, T. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res., 2004, 10, 7721-6.
118. Pal, A.; Ahmad, A.; Khan, S.; Sakabe, I.; Zhang, C.; Kasid, U.N.; Ahmad, I. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Oncol., 2005, 26, 1087-91.
119. Santel, A.; Aleku, M.; Keil, O.; Endruschat, J.; Esche, V.; Fisch, G.; Dames, S.; Loffler, K.; Fechtner, M.; Arnold, W.; Giese, K.; Klippel, A.; Kaufmann, J. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther., 2006, 13, 1222-34.
120. Semple, S.C.; Harasym, T.O.; Clow, K.A.; Ansell, S.M.; Klimuk, S.K.; Hope, M.J. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J. Pharmacol. Exp. Ther., 2005, 312, 1020-6.
121. Wang, X.; Ishida, T.; Kiwada, H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release, 2007, 119, 236-44.
122. Landen, C.N., Jr.; Chavez-Reyes, A.; Bucana, C.; Schmandt, R.; Deavers, M.T.; Lopez-Berestein, G.; Sood, A.K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res., 2005, 65, 6910-8.
123. Zimmermann, T.S.; Lee, A.C.; Akinc, A.; Bramlage, B.; Bumcrot, D.; Fedoruk, M.N.; Harborth, J.; Heyes, J.A.; Jeffs, L.B.; John, M.; Judge, A.D.; Lam, K.; McClintock, K.; Nechev, L.V.; Palmer, L.R.; Racie, T.; Rohl, I.; Seiffert, S.; Shanmugam, S.; Sood, V.; Soutschek, J.; Toudjarska, I.; Wheat, A.J.; Yaworski, E.; Zedalis, W.; Koteliansky, V.; Manoharan, M.; Vornlocher, H.P.; MacLachlan, I. RNAi-mediated gene silencing in non-human primates. Nature, 2006, 441, 111-4.
124. Watanabe, T.; Umehara, T.; Yasui, F.; Nakagawa, S.; Yano, J.; Ohgi, T.; Sonoke, S.; Satoh, K.; Inoue, K.; Yoshiba, M.; Kohara, M. Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome. J. Hepatol., 2007, 47, 744-50.
125. Sato, A.; Takagi, M.; Shimamoto, A.; Kawakami, S.; Hashida, M. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials, 2007, 28, 1434-42.
126. Audouy, S.A.; de Leij, L.F.; Hoekstra, D.; Molema, G. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm. Res., 2002, 19, 1599-605.
127. Ma, Z.; Li, J.; He, F.; Wilson, A.; Pitt, B.; Li, S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun., 2005, 330, 755-9.
128. Yan, W.; Chen, W.; Huang, L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol., 2007, 44, 3672-81.
129. Omidi, Y.; Hollins, A.J.; Benboubetra, M.; Drayton, R.; Benter, I.F.; Akhtar, S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J. Drug Target., 2003, 11, 311-23.
130. Ochiya, T.; Nagahara, S.; Sano, A.; Itoh, H.; Terada, M. Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr. Gene Ther., 2001, 1, 31-52.
131. Minakuchi, Y.; Takeshita, F.; Kosaka, N.; Sasaki, H.; Yamamoto, Y.; Kouno, M.; Honma, K.; Nagahara, S.; Hanai, K.; Sano, A.; Kato, T.; Terada, M.; Ochiya, T. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res., 2004, 32, e109.
132. Takeshita, F.; Minakuchi, Y.; Nagahara, S.; Honma, K.; Sasaki, H.; Hirai, K.; Teratani, T.; Namatame, N.; Yamamoto, Y.; Hanai, K.; Kato, T.; Sano, A.; Ochiya, T. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. USA, 2005, 102, 12177-82.
133. Matoba, T.; Orba, Y.; Suzuki, T.; Makino, Y.; Shichinohe, H.; Kuroda, S.; Ochiya, T.; Itoh, H.; Tanaka, S.; Nagashima, K.; Sawa, H. An siRNA against JC virus (JCV) agnoprotein inhibits JCV infection in JCV-producing cells inoculated in nude mice. Neuropathology, 2007.
134. Banno, H.; Takei, Y.; Muramatsu, T.; Komori, K.; Kadomatsu, K. Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J. Vasc. Surg., 2006, 44, 633-41.
135. Pille, J.Y.; Li, H.; Blot, E.; Bertrand, J.R.; Pritchard, L.L.; Opolon, P.; Maksimenko, A.; Lu, H.; Vannier, J.P.; Soria, J.; Malvy, C.; Soria, C. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther., 2006, 17, 1019-26.
136. Howard, K.A.; Rahbek, U.L.; Liu, X.; Damgaard, C.K.; Glud, S.Z.; Andersen, M.O.; Hovgaard, M.B.; Schmitz, A.; Nyengaard, J.R.; Besenbacher, F.; Kjems, J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther., 2006, 14, 476-84.
137. de Martimprey, H.; Bertrand, J.R.; Fusco, A.; Santoro, M.; Couvreur, P.; Vauthier, C.; Malvy, C. siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res., 2008, 36, e2.
138. Akhtar, S.; Benter, I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev., 2007, 59, 164-82.
139. Urban-Klein, B.; Werth, S.; Abuharbeid, S.; Czubayko, F.; Aigner, A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther., 2005, 12, 461-6.
140. Grzelinski, M.; Urban-Klein, B.; Martens, T.; Lamszus, K.; Bakowsky, U.; Hobel, S.; Czubayko, F.; Aigner, A. RNA interferencemediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther., 2006, 17, 751-66.
141. Schiffelers, R.M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P.Y.; Scaria, P.V.; Woodle, M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res., 2004, 32, e149.
142. Hu-Lieskovan, S.; Heidel, J.D.; Bartlett, D.W.; Davis, M.E.; Triche, T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res., 2005, 65, 8984-92.
143. Heidel, J.D.; Yu, Z.; Liu, J.Y.; Rele, S.M.; Liang, Y.; Zeidan, R.K.; Kornbrust, D.J.; Davis, M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA, 2007, 104, 5715-21.
144. Xiong, M.P.; Laird Forrest, M.; Ton, G.; Zhao, A.; Davies, N.M.; Kwon, G.S. Poly(aspartate-g-PEI800), a polyethylenimine analogue of low toxicity and high transfection efficiency for gene delivery. Biomaterials, 2007, 28, 4889-900.
145. Hoet, P.H.; Bruske-Hohlfeld, I.; Salata, O.V. Nanoparticles - known and unknown health risks. J. Nanobiotechnology, 2004, 2, 12.
146. Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J.; John, M.; Kesavan, V.; Lavine, G.; Pandey, R.K.; Racie, T.; Rajeev, K.G.; Rohl, I.; Toudjarska, I.; Wang, G.; Wuschko, S.; Bumcrot, D.; Koteliansky, V.; Limmer, S.; Manoharan, M.; Vornlocher, H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004, 432, 173-8.
147. Spagnou, S.; Miller, A.D.; Keller, M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry, 2004, 43, 13348-56.
148. Song, E.; Zhu, P.; Lee, S.K.; Chowdhury, D.; Kussman, S.; Dykxhoorn, D.M.; Feng, Y.; Palliser, D.; Weiner, D.B.; Shankar, P.; Marasco, W.A.; Lieberman, J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol., 2005, 23, 709-17.
149. McNamara, J.O., 2nd; Andrechek, E.R.; Wang, Y.; Viles, K.D.; Rempel, R.E.; Gilboa, E.; Sullenger, B.A.; Giangrande, P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol., 2006, 24, 1005-15.
150. Khan, A.; Benboubetra, M.; Sayyed, P.Z.; Ng, K.W.; Fox, S.; Beck, G.; Benter, I.F.; Akhtar, S. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J. Drug Target, 2004, 12, 393-404.
151. Murata, N.; Takashima, Y.; Toyoshima, K.; Yamamoto, M.; Okada, H. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control. Release, 2007.
152. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005, 438, 685-9.
153. Krutzfeldt, J.; Kuwajima, S.; Braich, R.; Rajeev, K.G.; Pena, J.; Tuschl, T.; Manoharan, M.; Stoffel, M. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res., 2007, 35, 2885-92.
154. Care, A.; Catalucci, D.; Felicetti, F.; Bonci, D.; Addario, A.; Gallo, P.; Bang, M.L.; Segnalini, P.; Gu, Y.; Dalton, N.D.; Elia, L.; Latronico, M.V.; Hoydal, M.; Autore, C.; Russo, M.A.; Dorn, G.W., 2nd; Ellingsen, O.; Ruiz-Lozano, P.; Peterson, K.L.; Croce, C.M.; Peschle, C.; Condorelli, G. MicroRNA-133 controls cardiac hypertrophy. Nat. Med., 2007, 13, 613-8.
155. Esau, C.; Davis, S.; Murray, S.F.; Yu, X.X.; Pandey, S.K.; Pear, M.; Watts, L.; Booten, S.L.; Graham, M.; McKay, R.; Subramaniam, A.; Propp, S.; Lollo, B.A.; Freier, S.; Bennett, C.F.; Bhanot, S.; Monia, B.P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab., 2006, 3, 87-98.
156. Ji, R.; Cheng, Y.; Yue, J.; Yang, J.; Liu, X.; Chen, H.; Dean, D.B.; Zhang, C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ. Res., 2007, 100, 1579-88.
157. Yang, B.; Lin, H.; Xiao, J.; Lu, Y.; Luo, X.; Li, B.; Zhang, Y.; Xu, C.; Bai, Y.; Wang, H.; Chen, G.; Wang, Z. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med., 2007, 13, 486-91.
158. Elmen, J.; Lindow, M.; Silahtaroglu, A.; Bak, M.; Christensen, M.; Lind-Thomsen, A.; Hedtjarn, M.; Hansen, J.B.; Hansen, H.F.; Straarup, E.M.; McCullagh, K.; Kearney, P.; Kauppinen, S. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res., 2008, 36, 1153-62.
159. Elmen, J.; Lindow, M.; Schutz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjarn, M.; Hansen, H.F.; Berger, U.; Gullans, S.; Kearney, P.; Sarnow, P.; Straarup, E.M.; Kauppinen, S. LNA-mediated microRNA silencing in non-human primates. Nature, 2008, 452, 896-9